Literature DB >> 31949679

Increased expression of osteopontin indicates poor prognosis in hepatocellular carcinoma.

Honghai Wang1, Donghui Guo1, Junjie Li1, Baolong Wei1, Hong Zheng1.   

Abstract

OBJECTIVE: To investigate the potential prognostic value of osteopontin (OPN) in hepatocellular carcinoma (HCC) patients after hepatectomy.
METHODS: A total of 384 HCC specimens with paired adjacent non-tumorous tissues from liver resections were collected to construct a tissue microarray for immunohistochemistry (IHC) analysis to detect the expression of OPN. OPN expression was semi-quantified with scores according to IHC staining. The potential correlations between OPN expression and neoplastic features of HCC were analyzed. The survivals in patients stratified with different OPN expression levels were calculated and compared. Uni- and multi-variate analysis were conducted to identify the potential prognostic value of OPN in HCC patients received liver resections.
RESULTS: The OPN in HCC tissues was 0.82 ± 0.68, significantly higher than that in matched nontumorous tissue (0.45 ± 0.59; P < 0.001). Higher OPN expression was associated with vascular invasion (P = 0.019). Patients with high OPN expression had worse overall survival (P < 0.001), disease-free survival (P = 0.045) and higher probability of recurrence (P = 0.048), compared with the patients of low OPN expression. Multivariate analysis indicated that OPN expression was an independent risk factor for overall survival (P = 0.045), disease-free survival (P = 0.048), and HCC recurrence (P = 0.044).
CONCLUSION: OPN expression was elevated in HCC tissues. High OPN expression was correlated with HCC vascular invasion. High OPN expression in HCC tissues is an independent factor for DFS and OS. OPN could be a predictor of HCC patients and a potential therapeutic target for the disease. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Osteopontin; biomarke; hepatocellular carcinoma; prognosis

Year:  2018        PMID: 31949679      PMCID: PMC6963100     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.

Authors:  Sahar Saad El-Din Bessa; Nadia Mohamed Elwan; Ghada Abdul Moemen Suliman; Safinaz Hamdy El-Shourbagy
Journal:  Arch Med Res       Date:  2010-10       Impact factor: 2.235

Review 2.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

3.  Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.

Authors:  Tae Seop Lim; Do Young Kim; Kwang-Hyub Han; Hyon-Suk Kim; Seung Hwan Shin; Kyu Sik Jung; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Sang Hoon Ahn
Journal:  Scand J Gastroenterol       Date:  2015-09-04       Impact factor: 2.423

Review 4.  Osteopontin -- a promising biomarker for cancer therapy.

Authors:  Ran Wei; Janet Pik Ching Wong; Hang Fai Kwok
Journal:  J Cancer       Date:  2017-07-15       Impact factor: 4.207

5.  Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs.

Authors:  Shaohang Cai; Zhandong Li; Tao Yu; Muye Xia; Jie Peng
Journal:  Infect Drug Resist       Date:  2018-04-03       Impact factor: 4.003

6.  Functional characterization of stromal osteopontin in melanoma progression and metastasis.

Authors:  Santosh Kumar; Priyanka Sharma; Dhiraj Kumar; Goutam Chakraborty; Mahadeo Gorain; Gopal C Kundu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

7.  Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB.

Authors:  Shao-hang Cai; Fang-fang Lv; Yong-hong Zhang; Ye-gui Jiang; Jie Peng
Journal:  BMC Infect Dis       Date:  2014-02-14       Impact factor: 3.090

Review 8.  Role of Osteopontin in Liver Diseases.

Authors:  Yankai Wen; Seogsong Jeong; Qiang Xia; Xiaoni Kong
Journal:  Int J Biol Sci       Date:  2016-08-06       Impact factor: 6.580

Review 9.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

10.  Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.

Authors:  Shaohang Cai; Jiawei Cao; Tao Yu; Muye Xia; Jie Peng
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

View more
  2 in total

1.  Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding.

Authors:  Suzanne Bartholf DeWitt; Sarah Hoskinson Plumlee; Hailey E Brighton; Dharshan Sivaraj; E J Martz; Maryam Zand; Vardhman Kumar; Maya U Sheth; Warren Floyd; Jacob V Spruance; Nathan Hawkey; Shyni Varghese; Jianhua Ruan; David G Kirsch; Jason A Somarelli; Ben Alman; William C Eward
Journal:  JCI Insight       Date:  2022-09-08

Review 2.  Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know.

Authors:  Jacek Baj; Łukasz Bryliński; Filip Woliński; Michał Granat; Katarzyna Kostelecka; Piotr Duda; Jolanta Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Marzena Furtak-Niczyporuk; Piero Portincasa
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.